Amino acid metabolism‐related gene expression‐based risk signature can better predict overall survival for glioma

• DOI: 10.1111/cas.13878
• Publication Date: 2018-11-15T19:56:01Z
• Authors: Yu‐Qing Liu; Rui‐Chao Chai; Yong‐Zhi Wang; Zheng Wang; Xing Liu; Fan Wu; Tao Jiang
• Keywords: Isocitrate dehydrogenase; Gene signature

Metabolic reprogramming has been proposed to be a hallmark of cancer. Aside from the glycolytic pathway, metabolic changes cancer cells primarily involve amino acid metabolism. However, in glioma, characteristics metabolism‐related gene set have not systematically profiled. In present study, RNA sequencing expression data 309 patients Chinese Glioma Genome Atlas database were included as training set, while another 550 within The Cancer used validate. Consensus clustering samples yielded two robust groups. Compared with Cluster1, Cluster2 correlated better clinical outcome. We then developed an risk signature for glioma. Our results showed that high‐risk group had dramatically shorter overall survival than low‐risk counterparts any subgroup, stratified by isocitrate dehydrogenase and 1p/19q status based on 2016 World Health Organization classification guidelines. 30‐gene prognostic value traditional factors “age” “grade” analyzing receiver operating characteristic curve areas under 0.966, 0.692, 0.898 0.975, 0.677, 0.885 3‐ 5‐year survival, respectively. Moreover, univariate multivariate analysis was independent factor Furthermore, Gene Ontology Set Enrichment Analysis tumors high score various aspects malignancy summary, we demonstrated novel predicting prognosis